A Global Study of the PETAL Consortium

Launched by MASSACHUSETTS GENERAL HOSPITAL · Sep 28, 2023

Keywords

ClinConnect Summary

The PETAL Consortium is a global study focused on understanding certain blood cancers called T-cell and NK-cell neoplasms. This study aims to find out how genetic changes in these cancers might affect patients’ survival and their response to treatment. Researchers believe that using advanced computer techniques, known as machine learning, can help identify specific genetic weaknesses in these cancers, which may explain why some patients respond well to treatment while others do not.

To participate, patients must have a confirmed diagnosis of mature T-cell or NK-cell neoplasm that is either untreated, relapsed, or has not responded to previous treatment. The study is open to adults aged 65 to 74, regardless of gender. Participants will be asked to provide information about their health and treatment outcomes, helping researchers gather valuable data. It’s important to note that certain types of T-cell and NK-cell neoplasms, as well as individuals unable to give their consent or young children, are not eligible for this study. By joining this trial, participants can contribute to important research that may improve treatment for others in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Untreated, relapsed, or refractory histologically confirmed mature T-cell or NK-cell neoplasm.
• • All subtypes of PTCL are eligible except for T-cell large granular lymphocytic leukemia, cutaneous T-cell lymphoma such as but not limited to mycosis fungoides and transformation, Sézary syndrome, and primary cutaneous CD30+ disorders.
• Exclusion Criteria:
• • Precursor T/NK neoplasms, T-cell large granular lymphocytic leukemia, cutaneous T-cell lymphoma such as but not limited to mycosis fungoides and transformation, Sézary syndrome, and primary cutaneous CD30+ disorders.
• • Adults who are unable to consent, individuals who are not yet adults such as infants, children and teenagers, pregnant women, and prisoners.